Can doctors and patients correctly estimate cardiovascular risk? A cross-sectional study in primary care

Su May Liew, Wai Khew Lee, Ee Ming Khoo, Irmi Zarina Ismail, Subashini Ambigapathy, Mimi Omar, Siti Zaleha Suleiman, Juwita Saaban, Nur Farhana Mohd Zaidi, Harmy Yusoff

ABSTRACT

Objective Accurate cardiovascular risk estimations by patients and doctors are important as these affect health behaviour and medical decision making. We aimed to determine if doctors and patients were accurately estimating the absolute cardiovascular risk of patients in primary care.

Methods A cross-sectional study was carried out in primary care clinics in Malaysia in 2014. Patients aged 35 years and above without known cardiovascular disease (CVDs) were included. Face-to-face interviews with a structured questionnaire were used to collect sociodemographic and clinical data as well as patients’ perception and doctors’ estimate of the patients’ CVD risk. Associations were tested using \( \chi^2 \), correlation and independent t-tests.

Results We recruited 1094 patients and 57 doctors. Using the Framingham Risk Score (FRS) alone, 508 patients (46.4%) were in the high-risk group. When diabetes was included as high risk, the number increased to 776 (70.9%). Only 34.4% of patients and 55.7% of doctors correctly estimated the patient’s CVD risk in comparison with the reference FRS. Of the high-risk patients, 664 (85.6%) underestimated their CV risk. Factors associated with underestimation by patients included not having family history of CVD (adjusted OR (AOR): 2.705, 95% CI 1.538 to 4.757), smaller waist circumference (AOR: 0.979, 95% CI 0.960 to 0.999) and ethnicity in comparison with the Malay as reference group (Indian: AOR: 0.430, 95% CI 0.271 to 0.677, Malay: AOR: 0.536, 95% CI 0.317 to 0.900). For doctors, non-diabetes (AOR: 1.931, 95% CI 1.114 to 3.348), non-hypertensive (AOR: 1.731, 95% CI 1.067 to 2.808), non-smoker (AOR: 2.246, 95% CI 1.460 to 3.410), younger age (AOR: 0.908, 95% CI 0.886 to 0.930), non-hypertensive (AOR: 1.731, 95% CI 1.067 to 2.808), non-diabetic (AOR: 1.931, 95% CI 1.114 to 3.348), higher high-density lipoprotein levels (AOR: 3.546, 95% CI 2.025 to 6.209), lower systolic blood pressure (AOR: 0.970, 95% CI 0.957 to 0.982), non-smoker (AOR: 2.246, 95% CI 1.354 to 3.726) and ethnicity in comparison with the Malay as reference group (indigenous/others: AOR: 0.129, 95% CI 0.071 to 0.235). A list of factors associated with underestimation by patients and doctors is shown in Table 1.

Conclusions The majority of consultations occurring between doctors and patients are being informed by inaccurate cardiovascular risk estimation.

Strengths and limitations of this study

- This was a large cross-sectional study that took place in nine different clinics and covered over a thousand patient consultations.
- It captured the perceptions and practices occurring in actual consultations in primary care settings where medical decisions were being made.
- Participants’ behaviour may have been affected due to awareness of the research being undertaken.

BACKGROUND

Despite international efforts, cardiovascular disease (CVD) remains the leading cause of death worldwide, killing more than 17 million people a year.1 Affordable, feasible and effective global actions capable of averting millions of deaths from non-communicable diseases have been identified to tackle this continuing crisis.2 Yet, the rate of non-communicable diseases, of which CVD is a major contributor, is increasing, and this increase is disproportionately greater in developing countries.3 Out of five interventions identified as priority actions for the non-communicable disease crisis,4 only one addressed individual clinical services, that is, access of essential drugs and technologies. This was deemed essential especially for those identified to be at high risk of CVD.

People at high risk of CVD can be identified using tools such as cardiovascular (CV) risk scores. These were designed to calculate an individual’s risk of developing a CV event from risk factors obtained from history, physical examination or investigations. Most guidelines recommend the use of risk scores to predict global risk rather than focusing on single risk modification. The majority advocates the use of Framingham Risk Score or scores that have been calibrated from the Framingham study data.1-6 A systematic review identified 21 risk scores for use in adults with...
no history of previous CVD. However, the use of the risk score is surprisingly limited. Studies have reported rates of use ranging from 17%–65%. Studies have shown that subjective estimation of CV risk by doctors is inaccurate. They tended to underestimate risk when the study used actual patients and overestimate risk for case reports or vignettes. Patients have also been found to be inaccurate in estimating their own CV risk. About 40% of the general population underestimates their CV risk and 20% overestimated it. In studies on those at established high CV risk, only about 40% were aware of their increased risk. Higher CV risk perception has been shown to be associated with better acceptance towards medical management regardless of whether the perception accurately reflected actual CV risk or not.

Accurate estimations of CV risk by both patients and doctors are important as these affect health behaviour and medical decision making. The proliferations of mobile health technology including online risk calculators and guidelines have shown potential in increasing awareness and use of CV risk scores in clinical consultations. But has this led to a corresponding improvement in the use of CV risk scores in practice? Our study aimed to determine if doctors and patients were able to accurately estimate the absolute CV risk of patients in a primary care health setting.

METHODOLOGY

This was a cross-sectional study carried out in nine public primary care clinics in Malaysia in 2014 with the period of recruitment from 1 to 30 November 2014. The nine clinics were chosen conveniently from five regions of Malaysia: two clinics each from the northern (Ipoh), southern (Melaka) and western regions (Klang Valley) and one clinic from the eastern region (Kelantan) of Peninsular Malaysia and two clinics from East Malaysia (Sabah). All patients attending these clinics aged 35 years and above with CV risk assessments done within the past year were included. Patients with known CVD, for example ischaemic heart disease and strokes, were excluded.

Based on a study, which found that 40%–52% of patients correctly estimated their CV risk, we used 50% to calculate the sample size, giving a total of 384 participants. After stratifying by regions, and taking into account a non-responder rate, a sample size of 998 was needed. Out of the 1107 patients approached, seven refused to participate and six did not fulfil the inclusion criteria, giving a total of 1094 patients recruited. The mean age was 57.2 years (SD 9.8) with a range of 35–86 years. There were 62.6% females, 60.8% had diabetes and 76.9% had hypertension (table 1). A total of 57 doctors participated in the study. The mean age of the doctors was 32.3 years (SD 5.5) with a mean duration of work experience of 6.5 years (SD 3.8). Women comprise 63.4% of the doctors.

Using the FRS alone, 508 patients (46.4%) were in the low-risk group. When diabetes was included, the number increased to 776 (70.9%). Of all the consultations, only (10%–20%) and high (>20%). Measurements were also taken for weight, height, waist circumference and blood pressure (BP) using a validated digital BP machine (OMRON HEM-7121). Doctors were also asked to fill up a questionnaire on their sociodemography, years of practice and the methods they used to estimate patients’ CV risks, if any.

We used the D’Agostino 2008 Framingham General Cardiovascular Risk Score Score (FRS) as the reference CVD risk. This has been validated for use in Malaysia without requiring adjustment for demographic variables such as ethnicity. The 10-year CVD risk is classified into low (<10%), moderate (10%–20%) and high (>20%) risk. In this study, high CVD risk group was defined as FRS >20% and/or presence of diabetes mellitus. Estimations made by the patients and doctors were deemed to be correct when there was agreement with the Framingham score as calculated by the research team; underestimation occurred when estimations were low or moderate in those scored as high risk by the research team.

ANALYSIS

Data were entered and analysed using Statistical Program for Social Sciences (SPSS) V.22.0. Complete-case analysis was used, meaning those with missing values were excluded. Frequencies were reported using percentages and proportions. Associations between categorical data were tested using χ² tests, while continuous data were tested using independent t-test and correlation test. Kappa value was calculated to determine the agreement between CV risks estimated by patient and actual risk, and CV risks estimated by doctors and actual risk. Univariate and multivariate binary logistic analyses were used, with underestimation of those at high risk as the outcome of interest. The intracluster correlation coefficient (ICC) was calculated to determine the homogeneity of the clusters. Values of ICC that are close to 0 indicate that the design effect is 1 and that the clusters are homogenous. The correlation estimates and the variant inflation factors (VIF) were used to determine multicollinearity among the explanatory variables.

RESULTS

Out of the 1107 patients approached, seven refused to participate and six did not fulfil the inclusion criteria, giving a total of 1094 patients recruited. The mean age was 57.2 years (SD 9.8) with a range of 35–86 years. There were 62.6% females, 60.8% had diabetes and 76.9% had hypertension (table 1). A total of 57 doctors participated in the study. The mean age of the doctors was 32.3 years (SD 5.5) with a mean duration of work experience of 6.5 years (SD 3.8). Women comprise 63.4% of the doctors.

Using the FRS alone, 508 patients (46.4%) were in the high-risk group. When diabetes was included, the number increased to 776 (70.9%). Of all the consultations, only
34.4% of patients and 55.7% of doctors correctly estimated the patient’s CVD risk group.

The ICC values calculated for all the variables were small, ranging from 0.001 to 0.086, indicating that the clusters are homogenous. The highest correlation between the variables is <0.85 (the highest being 0.780), while the highest VIF is <5. Hence, there is no multicollinearity within the variables.

Patients' estimation
Table 2 shows patients’ estimation of their CV risks. Among patients in high CV risk group, only 112 (14.4%) correctly estimated their risks. The remaining 664 (85.6%) underestimated their CV risk. The correlation between patients’ perceived CV risk and their actual risk was kappa=−0.016. Factors associated with underestimation by patients included not having family history of CVD (adjusted OR (AOR): 2.747, 95% CI 1.566 to 4.818), smaller waist circumference (AOR: 0.980, 95% CI 0.960 to 0.999) and ethnicity in comparison with the Malay as reference group (indigenous/others; AOR: 0.129, 95% CI 0.071 to 0.235) (table 3).

Doctors' estimation
Table 4 shows doctors' estimation of patients' CV risks. Among patients in high CV risk group, doctors correctly estimated 40.2% and underestimated 59.8%. The correlation between doctors’ estimation of patient’s CV risk versus patient’s actual CV risk was kappa=−0.084. Factors associated with underestimation of high CV risk by doctors were patients factors such as being female (AOR: 2.232, 95% CI 1.460 to 3.410), younger age (AOR: 0.908, 95% CI 0.886 to 0.930), non-hypertensive (AOR: 1.731, 95% CI 1.335 to 2.232), and having no family history of CVD (AOR: 1.379, 95% CI 1.218 to 1.562).

---

**Table 1** Sociodemography and profile of the respondents

| Demographic data and profile | Frequency (%) |
|------------------------------|---------------|
| Mean age±SD (years)          | 57.23±9.81    |
| Mean income±SD (Ringgit Malaysia) | 1824.34±2112.09 |
| Mean body mass index±SD (kg/m²) | 28.02±13.17   |
| Gender (female)              | 685 (62.6)    |
| Ethnicity                    |               |
| Malay                        | 559 (51.1)    |
| Chinese                      | 234 (21.4)    |
| Indian                       | 161 (14.7)    |
| Indigenous                   | 112 (10.2)    |
| Other                        | 28 (2.6)      |
| Smoker                       | 185 (16.9)    |
| Diabetes                     | 665 (60.8)    |
| Hypertension                 | 840 (76.8)    |
| Family history of stroke     | 165 (15.1)    |
| Family history of CVD disease | 158 (14.4)    |

**Table 3** Factors associated with underestimation of high CVD risk by patients

| Significance value | Adjusted OR | 95% CI Lower | 95% CI Upper |
|--------------------|-------------|--------------|--------------|
| Age                | 0.550       | 1.009        | 0.981        | 1.037        |
| Gender (female)    | 0.339       | 1.290        | 0.765        | 2.175        |
| Smoker (non-smoker)| 0.167       | 0.616        | 0.310        | 1.224        |
| Income             | 0.280       | 1.000        | 1.000        | 1.000        |
| Systolic BP        | 0.482       | 1.006        | 0.989        | 1.023        |
| Diastolic BP       | 0.194       | 0.982        | 0.955        | 1.009        |
| Waist circumference| 0.043       | 0.980        | 0.960        | 0.999        |
| Body mass index    | 0.230       | 0.981        | 0.952        | 1.012        |
| Total cholesterol  | 0.211       | 0.770        | 0.512        | 1.160        |
| LDL cholesterol    | 0.154       | 1.384        | 0.890        | 2.090        |
| HDL cholesterol    | 0.252       | 1.484        | 0.755        | 2.917        |
| Ethnicity          |             |              |              |              |
| Malay (reference)  | 1.0         |              |              |              |
| Chinese            | 0.430       | 1.335        | 0.651        | 2.738        |
| Indian             | 0.533       | 1.252        | 0.671        | 2.539        |
| Indigenous         | 0.000       | 0.129        | 0.071        | 0.235        |
| Hypertension       |             |              |              |              |
| Yes (reference)    | –            | 1.0          |              |              |
| No                 | 0.370       | 1.335        | 0.709        | 2.514        |
| Diabetes           |             |              |              |              |
| Yes (reference)    | –            | 1.0          |              |              |
| No                 | 0.596       | 1.230        | 0.572        | 2.644        |
| Antiplatelet use   |             |              |              |              |
| Yes (reference)    | –            | 1.0          |              |              |
| No                 | 0.523       | 1.186        | 0.703        | 2.000        |
| Statin use         |             |              |              |              |
| Yes (reference)    | –            | 1.0          |              |              |
| No                 | 0.739       | 0.905        | 0.504        | 1.626        |
| Family history with stroke | | | | |
| Yes (reference)    | –            | 1.0          |              |              |
| No                 | 0.198       | 1.494        | 0.811        | 2.753        |
| Family history with CVD | | | | |
| Yes (reference)    | –            | 1.0          |              |              |
| No                 | 0.001       | 2.705        | 1.538        | 4.757        |

BP, blood pressure; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein. p-values <0.05 are in bold.

---

Liew SM, et al. *BMJ Open* 2018;8:e017711. doi:10.1136/bmjopen-2017-017711
CI 1.067 to 2.808), non-diabetic (AOR: 1.931, 95% CI 1.114 to 3.348), higher HDL levels (AOR: 3.546, 95% CI 2.025 to 6.209), lower systolic BP (AOR: 0.970, 95% CI 0.957 to 0.982), non-smoker (AOR: 2.246, 95% CI 1.354 to 3.726) and ethnicity in comparison with the Malay as reference group (Indian: AOR: 0.430, 95% CI 0.257 to 0.720; indigenous/others: AOR: 2.498, 95% CI 1.346 to 4.636) (Table 5).

Table 6 summarises the methods used by doctors to estimate patients’ CV risk. About half used online risk calculators, while a quarter each used risk factor counting or manual calculation. Risk scores used included FRS, QRISK and American College of Cardiology/American Heart Association risk scores.

**DISCUSSION**

Our findings indicate that both patients and doctors were underestimating the patient’s CV risk. Of those at high CV risk, only one in seven patients could identify themselves as being at high risk. More worryingly, only two out of five doctors seeing these high CV risk patients could correctly identify them. This implies that medical decision making during these consultations were poorly informed due to inaccurate CV risk estimation.

How can this occur with the easy availability of online risk calculators and guidelines recommending use of risk estimation? It is likely that risk estimation for CVD is still poorly understood. Many CVD risk scores recommended using baseline levels of risk factors for risk calculation prior to the initiation of medication. For some risk scores such as the Adult Treatment Panel III risk calculator and the Pooled Cohort Risk score, diabetes is automatically taken as high CV risk without the need for calculation.26 27 Differences in the methods used by different risk scores and over time have led to misunderstandings, confusion and uncertainty by users.

A study that explored general practitioners’ use of CV risk scores found that doctors had great uncertainty over the use of CVD scores in treated patients.28 Use of patient’s risk factor levels when patient is on treatment would lead to an underestimation of the true CVD risk. Prolonged exposure to previous high levels and the presence of established chronic changes would mean that

| Table 4 | Doctor’s estimation of patient’s CV risk versus patient’s actual risk, n=1089 |
|-----------------|---------------------------------|-----------------|-----------------|-----------------|
| **Doctor’s estimation** | **Patient’s actual risk** | **High (n (%))** | **Low/moderate (n (%))** |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| High            | 310 (40.2)      | 20 (6.3)        |                 |                 |
| Low/moderate    | 462 (59.8)      | 297 (93.7)      |                 |                 |

CV, cardiovascular.

| Table 5 | Factors associated with doctor’s underestimation of patients’ actual risk |
|-----------------|---------------------------------|-----------------|-----------------|-----------------|
|                  | **Significance value** | **Adjusted OR** | **95% CI Lower** | **Upper** |
| **Doctors’ factors** |                      |                 |                 |                 |
| Age              | 0.771                | 0.988           | 0.911           | 1.071          |
| Experience       | 0.055                | 1.120           | 0.998           | 1.257          |
| Gender           |                      |                 |                 |                 |
| Male (reference) | _                   | 1.0             |                 |                 |
| Female           | 0.096                | 1.416           | 0.940           | 2.131          |
| **Patients’ factors** |                    |                 |                 |                 |
| Age              | **0.000**            | 0.908           | 0.886           | 0.930          |
| Income           | 0.052                | 1.000           | 1.000           | 1.000          |
| Waist circumference | 0.902               | 1.001           | 0.985           | 1.017          |
| Body mass index  | 0.530                | 0.994           | 0.975           | 1.013          |
| Systolic BP      | **0.000**            | 0.970           | 0.957           | 0.982          |
| Diastolic BP     | 0.121                | 1.017           | 0.996           | 1.038          |
| Total cholesterol | 0.471                | 0.899           | 0.672           | 1.202          |
| HDL Cholesterol  | **0.000**            | 3.546           | 2.025           | 6.209          |
| LDL Cholesterol  | 0.059                | 0.747           | 0.552           | 1.012          |
| **Gender**       |                      |                 |                 |                 |
| Male (reference) | _                   | 1.0             |                 |                 |
| Female           | **0.000**            | 2.232           | 1.460           | 3.410          |
| **Ethnicity**    |                      |                 |                 |                 |
| Malay (reference)| _                   | 1.0             |                 |                 |
| Chinese          | **0.727**            | 0.916           | 0.560           | 1.499          |
| Indian           | **0.001**            | 0.430           | 0.257           | 0.720          |
| Indigenous/others| **0.004**            | 2.498           | 1.346           | 4.636          |
| **Smoker**       |                      |                 |                 |                 |
| Yes (reference)  | _                   | 1.0             |                 |                 |
| No               | **0.002**            | 2.246           | 1.354           | 3.726          |
| **Hypertension** |                      |                 |                 |                 |
| Yes (reference)  | _                   | 1.0             |                 |                 |
| No               | **0.026**            | 1.731           | 1.067           | 2.808          |
| **Diabetes**     |                      |                 |                 |                 |
| Yes (reference)  | _                   | 1.0             |                 |                 |
| No               | **0.019**            | 1.931           | 1.114           | 3.348          |
| **Family history with CVD** |     |                 |                 |                 |
| Yes (reference)  | _                   | 1.0             |                 |                 |
| No               | 0.513                | 0.841           | 0.500           | 1.414          |
| **Family history with stroke** | |                 |                 |                 |
| Yes (reference)  | _                   | 1.0             |                 |                 |
| No               | 0.740                | 1.091           | 0.652           | 1.825          |
| **Antiplatelet use** |               |                 |                 |                 |
| Yes (reference)  | _                   | 1.0             |                 |                 |
| No               | 0.385                | 1.192           | 0.802           | 1.772          |
| **Statin use**   |                      |                 |                 |                 |
| Yes              | _                   | 1.0             |                 |                 |
| No               | 0.696                | 0.913           | 0.580           | 1.439          |

BP, blood pressure; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein. p-values <0.05 are in bold.
maximal reduction may take longer than 5 years and may never reach the level of a treatment-naïve patient. However, doctors find it difficult to obtain pretreatment levels, and overestimation would occur if the patient’s risk factor had been controlled over a long period of time.

Shared decision-making through proper risk communication ensures patients and doctors are able to weigh the risk and benefits of treatment options. The underestimation of risk as seen in this study population is likely to have significant impact on their management. Overoptimism has also been noted in other studies which described the tendency for people to be unrealistically optimistic about future life events. The research showed that subjects tended to be optimistic of their chances for negative events when the event is perceived to be controllable. This appears to mirror our finding where patients and doctors perceived the risk for CVD as being low because of the availability of treatment and behavioral lifestyle modification steps that can be taken. The mainstay of treatment of risk factors is to prevent progression of disease. Yet, patients and doctors must understand that residual risk remains and that treatment should be continued for most despite normalization of risk factor levels. This understanding is potentially jeopardized by optimism bias as adherence to medication and preventive behaviour have been shown to be associated with higher risk perception.

The findings also suggest that patients and doctors estimated risk by risk factor profile or risk factor counting as opposed to absolute risk calculation. It appears that there is good awareness of some of the risk factors for CVD as risk perception was found to be associated with these factors namely age, gender, comorbidities and smoking. However, focusing on individual risk factors or risk factor counting tends to underestimate risk in those who may have slightly elevated levels of multiple risk factors that synergistically increased the overall absolute CV risk. This is why most CVD guidelines advocate the use of risk calculators to estimate individual risk. Patients appeared to be more aware of family history and having a higher waist circumference as conferring risk compared with other risk factors. Family history and obesity have been shown to be associated with increased self-perception of risk. It is useful to identify factors that have greater meaning to patients. Otherwise, a mismatch between doctors' and patients' perception on the importance of particular risk factors can affect the communication of risk. The very low correlation between provider and patient estimates that we found in this study indicates that this mismatch is occurring.

Ethnicity also was found to be significantly associated with underestimation of risk. The AOR for underestimation of risk by doctors for patients of Indian ethnicity was 0.430, 95% CI 0.257 to 0.720 compared with the reference group (Malay patients). This indicates that in comparison with the Malay patients, underestimation of risk by doctors was less in patients of Indian ethnicity. It is possible that this is linked to training that those of South Asian ethnicity are at higher CVD risk. This finding can be used to target those at greater risk of inaccurate estimations for intervention.

**Strengths and limitations of the study**

This is a cross-sectional study that examined the risk perceptions of individual patients by both the patients and the doctors seeing these patients. The study design allowed us to capture the perceptions and practice occurring in actual consultations in primary care settings where decisions on institution of management for CVD prevention and treatment are made. This study took place in nine different clinics and covered over a thousand patient consultations.

It is possible that the doctors involved in this study may have been prompted to assess patients’ CV risk due to awareness of the research being undertaken as informed consent was obtained from all participants. However, we believe that this would only have prompted them to look up CV assessment. If knowledge of this study had introduced bias to the results, it would be likely that the direction of the bias would be towards more accurate estimation of risk. Hence, the rate of inaccurate risk estimation may actually be greater than was found.

This study used the validated FRS as the reference standard. Therefore, accuracy of estimations was based on agreement with the reference score and not to actual CV outcomes, which would require a cohort study design. We included patients aged 75 years and above, although the FRS is recommended for those aged 30–74 years of age. This decision was taken as it reflects the actual patient population that is seen in primary care. However, we understand that the risk score is less accurate when used outside the recommended age ranges.

**Recommendations**

In view of these findings, future studies should look at developing interventional strategies to implement formal CVD risk calculation into consultation and testing the strategies in actual consultations. Examples are system processes that incorporate risk calculators into electronic medical records or simple displays of risk charts on clinic desks. Accurate risk estimations should then be conveyed to patients to allow them to be fully informed when making decisions regarding their management in clinical practice.
CONCLUSION
The majority of consultations occurring between doctors and patients are being informed by inaccurate CV risk estimation. Inaccuracy is mainly due to underestimation of patients’ CVD risks. Interventions are required to improve CVD risk estimation in order to inform shared decision making in primary care consultations.

Acknowledgements
We would like to thank the DG of Health for approving the publication of this paper. We would also like to thank the director of CRC, MOH, Dr Goh Pik Pin for providing the platform for this research. We would also like to thank Dr Zukry from Klinik Kesihatan Keteri and all the clinics. The project was funded by the National Institute of Health, Malaysia.

Contributors
The study was conceived by SML, WKL, EMK, IZI and HY. SML, WKL, EMK, IZI, SA, MO, SJS, JS and HY contributed to the planning and data analysis of the study. WKL, IZI, SA, MO, SJS and JS assisted with data collection. NFMZ assisted with data analysis of the study. SML drafted the manuscript, and the final version was revised and approved by all authors.

Funding
National Institute of Health, Malaysia.

Competing interests
None declared.

Patient consent
Obtained.

Ethics approval
This study was registered in the National Medical Research Registry, Malaysia. (NMRR-13-962-17898) and approved by the Malaysian Research Ethics Committee. Potential participants were given verbal and written information regarding the study, and informed consent was obtained from those who were recruited.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data sharing statement
No additional data available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise stated in the text of the article or in this notice.

REFERENCES
1. Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol 2014;11:276–89.
2. Beaglesbough R, Bonita R, Horton R, et al. Priority actions for the non-communicable disease crisis. Lancet 2011;377:1438–47.
3. Heneghan C, Blacklock C, Perera R, et al. Evidence for non-communicable diseases: analysis of Cochrane reviews and randomised trials by World Bank classification. BMJ Open 2013;3:e003298.
4. National Institute for Health and Clinical Excellence. Change to lipid modification guideline CG67. 2010 http://www.nice.org.uk/newsroom/news/ChangeToLipidModificationGuidelineCG67.jsp (accessed 15 Aug 2011).
5. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52.
6. Tonkin A, Barter P, Best J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management—2005. Heart Lung Circ 2005;14:275–91.
7. Liew SM, Doust J, Glassiou P. Cardiovascular risk scores do not account for the effect of treatment: a review. Heart 2011;97:689–97.
8. Webster R, Heely E. Perceptions of risk; understanding cardiovascular disease. Risk Manag Healthc Policy 2010;3:49–60.
9. Sposito AC, Ramires JA, Jukema JW, et al. Physicians’ attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions. Curr Med Res Opin 2009;25:1171–8.
10. Dallongeville J, Banegas JR, Tubach F, et al. Survey of physicians’ practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prev Cardiol 2012;19:541–50.
11. Montgomery AA, Fahey T, MacIntosh C, et al. Estimation of cardiovascular risk in hypertensive patients in primary care. Br J Gen Pract 2000;50:127–8.
12. Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk perception and evidence—practice gaps in Australian general practice (the AusHEART study). Med J Aust 2010;192:254–9.
13. Friedmann PD, Brett AS, McKinnon MF. Differences in generalists’ and cardiologists’ perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med 1996;124:414–21.
14. Pignone M, Phillips CJ, Easley TA, et al. Physicians’ ability to predict the risk of coronary heart disease. BMC Health Serv Res 2003;3:13.
15. Grover SA, Lowenstein I, Esrey KL, et al. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary heart assessment study. BMJ 1995;310:975–8.
16. McManus RJ, Munt J, Meulendijks CF, et al. Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional study. BMJ 2002;324:459–64.
17. Avis NE, Smith KW, McKinlay JB. Accuracy of perceptions of heart attack risk: what influences perceptions and can they be changed? Am J Public Health 1989;79:1608–12.
18. Marteau TM, Kinmonth AL, Pyke S, et al. Readiness for lifestyle advice: self-assessments of coronary risk prior to screening in the British family heart study. Family Heart Study Group, Br J Gen Pract 1995;45:5–8.
19. Niknian M, McKinlay SM, Rakowski W, et al. A comparison of perceived and objective CVD risk in a general population. Am J Public Health 1989;79:1653–4.
20. Samsa GP, Cohen SJ, Goldstein LB, et al. Knowledge of risk among patients at increased risk for stroke. Stroke 1997;28:916–21.
21. Bonner G, Jansen JS, McKinlay S, et al. How do general practitioners and patients make decisions about cardiovascular disease risk? Health Psychol 2015;34:253–61.
22. Neubeck L, Lowres N, Benjamin EJ, et al. The mobile revolution—using smartphone apps to prevent cardiovascular disease. Nat Rev Cardiol 2015;12:396–407.
23. Selvarajah S, Kaur G, Hanif SJ, et al. Comparison of the Framingham Risk Score, SCORE and WHO/ISH cardiovascular risk prediction models in an Asian population. Int J Cardiol 2014;176:211–8.
24. Chia YC, Gray SY, Ching SM, et al. Validation of the Framingham general cardiovascular risk score in a multiethnic Asian population: a retrospective cohort study. BMJ Open 2015;5:e007324.
25. Killip S, Mahfoud Z, Pearce K. What is an intracluster correlation coefficient? Crucial concepts for primary care researchers. Ann Fam Med 2004;2:204–8.